Agomab’s ALK5 inhibitor has proven its ability to target the correct part of the intestine in a phase 2 trial of fibrostenosing Crohn’s disease. The STENOVA study saw 90 patients with the ...
MedPage Today on MSN13d
Avoidable Cancers After Colonoscopy; Real-World Rinvoq Data; Drug Flops in IBS TrialResearchers in Gastroenterology evaluated strategies for preventing avoidable colorectal cancers after colonoscopy. In ...
Belgian biotech Agomab Therapeutics (Nasdaq: AGMB) has reported positive interim results from its Phase IIa STENOVA trial of AGMB-129, an oral gut-restricted small molecule ALK5 inhibitor in ...
Belgium-based Agomab will use some of the proceeds to fund a recently-started phase 2 trial of its lead ALK5 inhibitor AGMB-129 for fibrostenosing Crohn’s disease, a severe form that often ...
Its efficacy and safety have not been established. AGMB-129 is an oral, small molecule GI-restricted inhibitor of ALK5 (or TGF-β RI) currently in clinical development for the treatment of ...
Agomab Therapeutics NV (‘Agomab’) today announced positive interim results from 44 patients completing treatment in the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback